Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGE NASDAQ:IMNM NASDAQ:KYMR NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$132.91$93.59$34.34▼$133.85$8.23B0.325.87 million shs3.00 million shsIMNMImmunome$23.61$20.96$7.96▼$27.65$2.67B2.071.73 million shs1.87 million shsKYMRKymera Therapeutics$113.51$87.36$36.65▼$130.05$9.34B1.951.27 million shs788,284 shsTGTXTG Therapeutics$53.31$43.98$25.28▼$57.38$8.16B1.63.03 million shs3.04 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics0.00%+0.27%+57.87%+57.59%+199.89%IMNMImmunome0.00%+18.29%+19.18%+8.10%+173.58%KYMRKymera Therapeutics0.00%+4.99%+55.11%+32.92%+154.91%TGTXTG Therapeutics0.00%-4.51%+32.91%+58.99%+46.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$132.91$93.59$34.34▼$133.85$8.23B0.325.87 million shs3.00 million shsIMNMImmunome$23.61$20.96$7.96▼$27.65$2.67B2.071.73 million shs1.87 million shsKYMRKymera Therapeutics$113.51$87.36$36.65▼$130.05$9.34B1.951.27 million shs788,284 shsTGTXTG Therapeutics$53.31$43.98$25.28▼$57.38$8.16B1.63.03 million shs3.04 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics0.00%+0.27%+57.87%+57.59%+199.89%IMNMImmunome0.00%+18.29%+19.18%+8.10%+173.58%KYMRKymera Therapeutics0.00%+4.99%+55.11%+32.92%+154.91%TGTXTG Therapeutics0.00%-4.51%+32.91%+58.99%+46.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 2.24Hold$121.25-8.77% DownsideIMNMImmunome 2.85Moderate Buy$33.1740.48% UpsideKYMRKymera Therapeutics 2.96Moderate Buy$121.416.96% UpsideTGTXTG Therapeutics 2.75Moderate Buy$58.609.92% UpsideCurrent Analyst Ratings BreakdownLatest IMNM, KYMR, TGTX, and APGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2026KYMRKymera Therapeutics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$110.00 ➝ $125.006/29/2026KYMRKymera Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$117.00 ➝ $155.006/29/2026KYMRKymera Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$116.00 ➝ $136.006/26/2026KYMRKymera Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$106.00 ➝ $129.006/25/2026KYMRKymera Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$134.006/24/2026APGEApogee Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$110.00 ➝ $135.006/24/2026APGEApogee Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Hold$110.00 ➝ $135.006/24/2026APGEApogee Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$133.00 ➝ $135.006/23/2026APGEApogee Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold6/23/2026APGEApogee Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral6/23/2026APGEApogee Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$100.00 ➝ $135.11(Data available from 7/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$13.23 per shareN/AIMNMImmunome$6.94M385.28N/AN/A$5.75 per share4.11KYMRKymera Therapeutics$39.21M238.14N/AN/A$19.42 per share5.85TGTXTG Therapeutics$616.29M13.24$2.80 per share19.02$4.08 per share13.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$255.84M-$4.33N/AN/AN/AN/A-32.64%-31.25%8/10/2026 (Estimated)IMNMImmunome-$212.39M-$2.38N/AN/AN/AN/A-51.15%-47.32%8/5/2026 (Estimated)KYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%8/10/2026 (Estimated)TGTXTG Therapeutics$447.18M$2.8618.6419.392.1865.95%88.73%43.44%8/3/2026 (Estimated)Latest IMNM, KYMR, TGTX, and APGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026IMNMImmunome-$0.60-$0.48+$0.12-$0.48$0.22 millionN/A5/11/2026Q1 2026APGEApogee Therapeutics-$1.0658-$1.06+$0.0058-$1.06N/AN/A5/6/2026Q1 2026TGTXTG Therapeutics$0.23$0.12-$0.11$0.12$200.33 million$204.92 million4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A32.5932.59IMNMImmunomeN/A21.6821.68KYMRKymera TherapeuticsN/A10.8110.81TGTXTG Therapeutics1.285.815.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%IMNMImmunome44.58%KYMRKymera TherapeuticsN/ATGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics24.30%IMNMImmunome7.21%KYMRKymera Therapeutics15.98%TGTXTG Therapeutics8.87%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9161.90 million46.86 millionOptionableIMNMImmunome40113.25 million105.09 millionOptionableKYMRKymera Therapeutics17082.26 million69.11 millionOptionableTGTXTG Therapeutics290153.08 million139.51 millionOptionableIMNM, KYMR, TGTX, and APGE HeadlinesRecent News About These CompaniesWill Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?July 3 at 9:55 AM | zacks.comTG Therapeutics Surged 88%: Time To Be More Careful (Rating Downgrade)June 29, 2026 | seekingalpha.comIs TG Therapeutics, Inc. (TGTX) A Good Stock To Buy Now?June 19, 2026 | insidermonkey.comIs TG Therapeutics, Inc. (TGTX) A Good Stock To Buy Now?June 19, 2026 | finance.yahoo.comTG Therapeutics Stock Rises Thursday: What's Driving The Gains?June 18, 2026 | benzinga.comTGTX Stock Continues Rally For 8 Straight Sessions On New BRIUMVI Clinical DataJune 17, 2026 | msn.comTG Therapeutics stock is on a hot streak: Why it's up 70% and climbingJune 17, 2026 | msn.comTG Therapeutics, Inc. $TGTX Shares Sold by WINTON GROUP LtdJune 11, 2026 | marketbeat.comTG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?June 11, 2026 | zacks.comWhy TG Therapeutics (TGTX) Is Up 18.4% After Advancing At‑Home Subcutaneous BRIUMVI In MS TreatmentJune 10, 2026 | finance.yahoo.comTGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MGJune 10, 2026 | zacks.comTGTX Stock Jumps 5% On Positive Early Data For At-Home BRIUMVI In Muscle DiseaseJune 10, 2026 | finance.yahoo.comTG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comTG Thera posts early-stage data for Briumvi in myasthenia gravis; launches mid-stage trialJune 9, 2026 | seekingalpha.comTG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized ...June 9, 2026 | finance.yahoo.comA Look At TG Therapeutics (TGTX) Valuation After Recent Positive BRIUMVI Trial UpdatesJune 9, 2026 | finance.yahoo.comTG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 TrialJune 9, 2026 | globenewswire.comB. Riley Securities Remains a Buy on TG Therapeutics (TGTX)June 8, 2026 | theglobeandmail.comWhy Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?June 5, 2026 | zacks.comTG Therapeutics rises on early-stage trial data for Briumvi injectableJune 4, 2026 | seekingalpha.comTGTX Stock Applies Brakes On 5-Session Losing Streak – Retail Eyes ‘Multi-Billion’ Sales As At-Home Multiple Sclerosis Treatment Gets BoostJune 4, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMNM, KYMR, TGTX, and APGE Company DescriptionsApogee Therapeutics NASDAQ:APGE$132.91 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$133.47 +0.56 (+0.42%) As of 07/2/2026 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Immunome NASDAQ:IMNM$23.61 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$22.54 -1.07 (-4.53%) As of 07/2/2026 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Kymera Therapeutics NASDAQ:KYMR$113.51 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$114.00 +0.49 (+0.43%) As of 07/2/2026 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.TG Therapeutics NASDAQ:TGTX$53.31 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$53.35 +0.04 (+0.07%) As of 07/2/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
